O	0	5	Three
O	5	6	-
O	6	10	year
O	11	17	follow
O	17	18	-
O	18	20	up
O	21	25	from
O	26	27	a
O	28	33	phase
O	34	35	3
O	36	41	study
O	42	44	of
B-intervention	45	48	SB3
I-intervention	49	50	(
I-intervention	50	51	a
I-intervention	52	63	trastuzumab
I-intervention	64	74	biosimilar
I-intervention	74	75	)
O	76	82	versus
B-control	83	92	reference
I-control	93	104	trastuzumab
O	105	107	in
O	108	111	the
O	112	123	neoadjuvant
O	124	131	setting
O	132	135	for
O	136	141	human
O	142	151	epidermal
O	152	158	growth
O	159	165	factor
O	166	174	receptor
O	175	176	2
O	176	177	-
O	177	185	positive
O	186	192	breast
O	193	199	cancer
O	199	200	.

O	201	203	We
O	204	212	assessed
O	213	217	long
O	217	218	-
O	218	222	term
O	223	230	cardiac
O	231	237	safety
O	238	241	and
O	242	250	efficacy
O	251	253	in
O	254	262	patients
O	263	267	with
O	268	273	human
O	274	283	epidermal
O	284	290	growth
O	291	297	factor
O	298	306	receptor
O	307	308	2
O	308	309	-
O	309	317	positive
O	318	323	early
O	324	330	breast
O	331	337	cancer
O	338	345	treated
O	346	350	with
O	351	352	a
O	353	364	trastuzumab
O	365	375	biosimilar
O	376	377	(
O	377	380	SB3
O	380	381	)
O	382	384	or
O	385	388	its
O	389	398	reference
O	399	406	product
O	406	407	,
O	408	419	trastuzumab
O	420	421	(
O	421	424	TRZ
O	424	425	)
O	425	426	,
O	427	429	in
O	430	431	a
O	432	437	phase
O	438	439	3
O	440	445	study
O	445	446	.

O	447	455	Patients
O	456	459	who
O	460	469	completed
O	470	473	the
O	474	479	phase
O	480	481	3
O	482	487	study
O	488	493	could
O	494	496	be
O	497	505	enrolled
O	506	508	in
O	509	513	this
O	514	523	extension
O	524	529	study
O	529	530	.

O	531	534	The
O	535	543	outcomes
O	544	552	included
O	553	556	the
O	557	566	incidence
O	567	569	of
O	570	581	symptomatic
O	582	592	congestive
O	593	598	heart
O	599	606	failure
O	607	608	(
O	608	611	CHF
O	611	612	)
O	612	613	,
O	614	626	asymptomatic
O	627	638	significant
O	639	643	left
O	644	655	ventricular
O	656	664	ejection
O	665	673	fraction
O	674	675	(
O	675	679	LVEF
O	679	680	)
O	681	689	decrease
O	689	690	,
O	691	700	incidence
O	701	703	of
O	704	709	other
O	710	717	cardiac
O	718	724	events
O	724	725	,
O	726	731	event
O	731	732	-
O	732	736	free
O	737	745	survival
O	746	747	(
O	747	750	EFS
O	750	751	)
O	751	752	,
O	753	756	and
O	757	764	overall
O	765	773	survival
O	773	774	.

O	775	777	In
O	778	782	post
O	783	786	hoc
O	787	795	analysis
O	795	796	,
O	797	800	the
O	801	804	Cox
O	805	817	proportional
O	818	825	hazards
O	826	836	regression
O	837	842	model
O	843	846	was
O	847	851	used
O	852	854	to
O	855	861	assess
O	862	869	factors
O	870	880	associated
O	881	885	with
O	886	889	EFS
O	889	890	.

O	891	892	A
O	893	898	total
O	899	901	of
B-total-participants	902	905	367
O	906	914	patients
O	915	919	were
O	920	928	enrolled
O	929	931	in
O	932	935	the
O	936	941	study
O	942	943	(
O	943	946	SB3
O	946	947	,
O	948	949	n
O	950	951	=
B-intervention-participants	952	955	186
O	955	956	;
O	957	960	TRZ
O	960	961	,
O	962	963	n
O	964	965	=
B-control-participants	966	969	181
O	969	970	)
O	970	971	.

O	972	975	The
O	976	982	median
O	983	989	follow
O	989	990	-
O	990	992	up
O	993	1001	duration
O	1002	1006	from
O	1007	1010	the
O	1011	1015	main
O	1016	1021	study
O	1022	1031	enrolment
O	1032	1035	was
O	1036	1038	40
O	1038	1039	.
O	1039	1040	8
O	1041	1044	and
O	1045	1047	40
O	1047	1048	.
O	1048	1049	5
O	1050	1056	months
O	1057	1060	for
O	1061	1064	SB3
O	1065	1068	and
O	1069	1072	TRZ
O	1072	1073	,
O	1074	1086	respectively
O	1086	1087	.

O	1088	1094	During
O	1095	1098	the
O	1099	1102	two
O	1102	1103	-
O	1103	1107	year
O	1108	1114	follow
O	1114	1115	-
O	1115	1117	up
O	1118	1123	after
O	1124	1132	adjuvant
O	1133	1140	therapy
O	1140	1141	,
O	1142	1151	incidence
O	1152	1154	of
O	1155	1167	asymptomatic
O	1168	1179	significant
B-outcome	1180	1184	LVEF
O	1185	1193	decrease
O	1194	1197	was
O	1198	1202	rare
O	1203	1204	(
O	1204	1207	SB3
O	1207	1208	,
O	1209	1210	n
O	1211	1212	=
B-iv-bin-abs	1213	1214	1
O	1214	1215	;
O	1216	1219	TRZ
O	1219	1220	,
O	1221	1222	n
O	1223	1224	=
B-cv-bin-abs	1225	1226	2
O	1226	1227	)
O	1227	1228	,
O	1229	1233	with
O	1234	1237	all
O	1238	1246	patients
O	1247	1257	recovering
O	1258	1262	with
O	1263	1267	LVEF
O	1268	1269	â‰¥
O	1270	1272	50
O	1272	1273	%
O	1273	1274	,
O	1275	1278	and
O	1279	1281	no
O	1282	1287	cases
O	1288	1290	of
O	1291	1302	symptomatic
O	1303	1306	CHF
O	1307	1309	or
O	1310	1315	other
O	1316	1323	cardiac
O	1324	1330	events
O	1331	1335	were
O	1336	1344	reported
O	1344	1345	.

O	1346	1348	At
O	1349	1350	3
O	1351	1356	years
O	1356	1357	,
O	1358	1361	the
B-outcome	1362	1365	EFS
O	1366	1369	was
B-iv-bin-percent	1370	1372	91
I-iv-bin-percent	1372	1373	.
I-iv-bin-percent	1373	1374	9
I-iv-bin-percent	1374	1375	%
O	1376	1380	with
O	1381	1384	SB3
O	1385	1388	and
B-cv-bin-percent	1389	1391	85
I-cv-bin-percent	1391	1392	.
I-cv-bin-percent	1392	1393	2
I-cv-bin-percent	1393	1394	%
O	1395	1399	with
O	1400	1403	TRZ
O	1403	1404	.

O	1405	1408	The
B-outcome	1409	1415	number
I-outcome	1416	1418	of
I-outcome	1419	1427	patients
I-outcome	1428	1432	with
I-outcome	1433	1439	events
O	1440	1443	was
B-iv-bin-abs	1444	1446	17
O	1447	1448	(
B-iv-bin-percent	1448	1449	9
I-iv-bin-percent	1449	1450	.
I-iv-bin-percent	1450	1451	1
I-iv-bin-percent	1451	1452	%
O	1452	1453	)
O	1454	1458	with
O	1459	1462	SB3
O	1463	1466	and
B-cv-bin-abs	1467	1469	31
O	1470	1471	(
B-cv-bin-percent	1471	1473	17
I-cv-bin-percent	1473	1474	.
I-cv-bin-percent	1474	1475	1
I-cv-bin-percent	1475	1476	%
O	1476	1477	)
O	1478	1482	with
O	1483	1486	TRZ
O	1487	1488	[
O	1488	1494	hazard
O	1495	1500	ratio
O	1500	1501	:
O	1502	1503	0
O	1503	1504	.
O	1504	1506	47
O	1506	1507	,
O	1508	1510	95
O	1510	1511	%
O	1512	1522	confidence
O	1523	1531	interval
O	1531	1532	:
O	1533	1534	0
O	1534	1535	.
O	1535	1537	26
O	1537	1538	-
O	1538	1539	0
O	1539	1540	.
O	1540	1542	87
O	1542	1543	]
O	1543	1544	.

O	1545	1553	Antibody
O	1553	1554	-
O	1554	1563	dependent
O	1564	1568	cell
O	1568	1569	-
O	1569	1577	mediated
O	1578	1590	cytotoxicity
O	1591	1592	(
O	1592	1596	ADCC
O	1596	1597	)
O	1598	1606	activity
O	1607	1610	and
O	1611	1614	the
O	1615	1621	breast
B-outcome	1622	1632	pathologic
I-outcome	1633	1641	complete
I-outcome	1642	1650	response
I-outcome	1651	1655	rate
O	1656	1660	were
O	1661	1664	the
O	1665	1672	factors
O	1673	1683	associated
O	1684	1688	with
O	1689	1692	EFS
O	1692	1693	.

B-outcome	1694	1708	Cardiotoxicity
O	1709	1712	was
O	1713	1717	rare
O	1718	1720	in
O	1721	1725	this
O	1726	1735	extension
O	1736	1741	study
O	1741	1742	.

O	1743	1746	EFS
O	1747	1750	was
O	1751	1757	higher
O	1758	1762	with
O	1763	1766	SB3
O	1767	1773	versus
O	1774	1777	TRZ
O	1777	1778	,
O	1779	1783	with
O	1784	1788	post
O	1789	1792	hoc
O	1793	1801	analysis
O	1802	1812	suggesting
O	1813	1817	that
O	1818	1819	a
O	1820	1828	downward
O	1829	1834	drift
O	1835	1837	in
O	1838	1842	ADCC
O	1843	1851	activity
O	1852	1855	was
O	1856	1857	a
O	1858	1870	contributing
O	1871	1877	factor
O	1877	1878	.

O	1879	1890	NCT02771795
O	1891	1892	(
O	1892	1899	EudraCT
O	1900	1904	2015
O	1904	1905	-
O	1905	1911	005663
O	1911	1912	-
O	1912	1914	17
O	1914	1915	)
O	1915	1916	.
